No Data
Shandong Buchang Pharmaceuticals (603858.SH): The subsidiary has once again passed the recognition as a high-tech enterprise.
On May 6, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that its wholly-owned subsidiary Baoding Tianhao Pharmaceutical Co., Ltd. (hereinafter referred to as "Baoding Tianhao") received the "High-tech Enterprise Certificate" issued by the Hebei Provincial Department of Industry and Information Technology, Hebei Provincial Department of Finance, and the State Administration of Taxation Hebei Provincial Taxation Bureau. Baoding Tianhao has passed the re-certification as a high-tech enterprise, certificate number: GR202413001351, issued on November 11, 2024, valid for three years. The recognition as a high-tech enterprise marks that Baoding Tianhao possesses strong innovative research and development capabilities.
Shandong Buchang Pharmaceuticals (603858.SH): has cumulatively repurchased 0.6% of its shares.
On May 6, Glonghui announced that Shandong Buchang Pharmaceuticals (603858.SH) has repurchased a total of 6,620,630 shares through centralized bidding transactions as of April 30, 2025, accounting for 0.60% of the company's total equity. The highest purchase price was 15.07 yuan/share, the lowest price was 13.86 yuan/share, and the total amount paid so far is 98,037,536.97 yuan (excluding transaction costs).
Buchang Pharma's Unit Gets Nod to Amend Manufacturing License
Shandong Buchang Pharmaceuticals (603858.SH): There are currently no research and development plans for tablet forms of Wuxin granules.
Gelonghui, April 30 – Shandong Buchang Pharmaceuticals (603858.SH) stated on the interactive platform that the company currently has no research and development plans for the tablet form of the stable heart granules.
Shandong Buchang Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Summary of the 2024 Annual Report of Shandong Buchang Pharmaceutical Co., Ltd.
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
